C
Cipher Pharmaceuticals Inc.
CPHRF
$7.85
-$0.07-0.88%
C
Hold
11/8/2024Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to C+ from B- on 11/8/2024 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.12 to $0.01, the quick ratio declined from 10.53 to 1.57, and operating cash flow declined 67.84% from $6.23M to $2M.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to C+ from B- on 11/8/2024 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.12 to $0.01, the quick ratio declined from 10.53 to 1.57, and operating cash flow declined 67.84% from $6.23M to $2M.
B
Buy
6/28/2024Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to B- from B on 6/28/2024 due to a decline in the total return index and volatility index.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to B- from B on 6/28/2024 due to a decline in the total return index and volatility index.
B
Buy
5/28/2024Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to B from B- on 5/28/2024 due to an increase in the solvency index, growth index and volatility index. EBIT increased 28.96% from $2.37M to $3.06M, total revenue increased 19.25% from $4.92M to $5.87M, and operating cash flow increased 0.75% from $2.42M to $2.43M.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to B from B- on 5/28/2024 due to an increase in the solvency index, growth index and volatility index. EBIT increased 28.96% from $2.37M to $3.06M, total revenue increased 19.25% from $4.92M to $5.87M, and operating cash flow increased 0.75% from $2.42M to $2.43M.
B
Buy
2/15/2024Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to B- from C on 2/15/2024 due to a significant increase in the total return index, growth index and efficiency index. Net income increased 128.95% from $3.07M to $7.03M, earnings per share increased from $0.12 to $0.27, and operating cash flow increased 102.72% from $2.95M to $5.97M.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to B- from C on 2/15/2024 due to a significant increase in the total return index, growth index and efficiency index. Net income increased 128.95% from $3.07M to $7.03M, earnings per share increased from $0.12 to $0.27, and operating cash flow increased 102.72% from $2.95M to $5.97M.
C
Hold
1/21/2022Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to C from C+ on 1/21/2022 due to a large decline in the total return index, growth index and solvency index. Operating cash flow declined 84.39% from $3.26M to $509, earnings per share declined from $0.1 to $0.03, and EBIT declined 47.12% from $3.82M to $2.02M.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to C from C+ on 1/21/2022 due to a large decline in the total return index, growth index and solvency index. Operating cash flow declined 84.39% from $3.26M to $509, earnings per share declined from $0.1 to $0.03, and EBIT declined 47.12% from $3.82M to $2.02M.
C
Hold
11/5/2021Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C+ from C on 11/5/2021 due to a noticeable increase in the total return index, solvency index and volatility index.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C+ from C on 11/5/2021 due to a noticeable increase in the total return index, solvency index and volatility index.
C
Hold
8/13/2021Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C from C- on 8/13/2021 due to a significant increase in the growth index, total return index and valuation index. Earnings per share increased from $0.0498 to $0.1, EBIT increased 14.85% from $3.33M to $3.82M, and total revenue increased 12.52% from $5.45M to $6.13M.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C from C- on 8/13/2021 due to a significant increase in the growth index, total return index and valuation index. Earnings per share increased from $0.0498 to $0.1, EBIT increased 14.85% from $3.33M to $3.82M, and total revenue increased 12.52% from $5.45M to $6.13M.
C
Hold
6/10/2021Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C- from D+ on 6/10/2021 due to an increase in the volatility index and total return index.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C- from D+ on 6/10/2021 due to an increase in the volatility index and total return index.
D
Sell
5/14/2021Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D+ from C on 5/14/2021 due to a significant decline in the growth index, valuation index and volatility index. Operating cash flow declined 30.33% from $6.21M to $4.33M, total revenue declined 11.4% from $6.15M to $5.45M, and EBIT declined 3.26% from $3.44M to $3.33M.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D+ from C on 5/14/2021 due to a significant decline in the growth index, valuation index and volatility index. Operating cash flow declined 30.33% from $6.21M to $4.33M, total revenue declined 11.4% from $6.15M to $5.45M, and EBIT declined 3.26% from $3.44M to $3.33M.
C
Hold
4/20/2021Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C from C- on 4/20/2021 due to an increase in the total return index and volatility index.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C from C- on 4/20/2021 due to an increase in the total return index and volatility index.
C
Hold
3/24/2021Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C- from D+ on 3/24/2021 due to an increase in the solvency index, growth index and total return index. Operating cash flow increased 438.53% from -$1.84M to $6.21M, debt to equity declined from 0.05 to 0, and EBIT increased 38.29% from $2.49M to $3.44M.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C- from D+ on 3/24/2021 due to an increase in the solvency index, growth index and total return index. Operating cash flow increased 438.53% from -$1.84M to $6.21M, debt to equity declined from 0.05 to 0, and EBIT increased 38.29% from $2.49M to $3.44M.
D
Sell
11/3/2020Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D+ from C- on 11/3/2020 due to a decline in the volatility index, total return index and growth index.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D+ from C- on 11/3/2020 due to a decline in the volatility index, total return index and growth index.
C
Hold
10/19/2020Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C- from D+ on 10/19/2020 due to an increase in the volatility index and valuation index.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C- from D+ on 10/19/2020 due to an increase in the volatility index and valuation index.
D
Sell
9/29/2020Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D+ from C- on 9/29/2020 due to a decline in the total return index, growth index and efficiency index. Net income declined 84.44% from $2.64M to $411, earnings per share declined from $0.0961 to $0.0152, and operating cash flow declined 64.3% from $5.39M to $1.92M.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D+ from C- on 9/29/2020 due to a decline in the total return index, growth index and efficiency index. Net income declined 84.44% from $2.64M to $411, earnings per share declined from $0.0961 to $0.0152, and operating cash flow declined 64.3% from $5.39M to $1.92M.
C
Hold
8/12/2020Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C- from D+ on 8/12/2020 due to a noticeable increase in the total return index.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to C- from D+ on 8/12/2020 due to a noticeable increase in the total return index.
D
Sell
6/18/2020Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D+ from D on 6/18/2020 due to an increase in the volatility index, total return index and valuation index.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D+ from D on 6/18/2020 due to an increase in the volatility index, total return index and valuation index.
D
Sell
5/29/2020Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D from D+ on 5/29/2020 due to a decline in the volatility index and valuation index.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D from D+ on 5/29/2020 due to a decline in the volatility index and valuation index.
D
Sell
5/13/2020Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D+ from D on 5/13/2020 due to an increase in the efficiency index, volatility index and solvency index. Debt to equity declined from 0.28 to 0.19, the quick ratio increased from 0.92 to 1.2, and total capital increased 1.39% from $37.58M to $38.1M.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D+ from D on 5/13/2020 due to an increase in the efficiency index, volatility index and solvency index. Debt to equity declined from 0.28 to 0.19, the quick ratio increased from 0.92 to 1.2, and total capital increased 1.39% from $37.58M to $38.1M.
D
Sell
3/27/2020Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D from D- on 3/27/2020 due to a significant increase in the valuation index, growth index and efficiency index. Earnings per share increased from -$0.0771 to $0.1165, net income increased 249.66% from -$2.08M to $3.11M, and operating cash flow increased 16.13% from $1.69M to $1.97M.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D from D- on 3/27/2020 due to a significant increase in the valuation index, growth index and efficiency index. Earnings per share increased from -$0.0771 to $0.1165, net income increased 249.66% from -$2.08M to $3.11M, and operating cash flow increased 16.13% from $1.69M to $1.97M.
D
Sell
3/25/2020Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D- from D on 3/25/2020 due to a significant decline in the valuation index, growth index and total return index. Earnings per share declined from $0.0513 to -$0.0771, and operating cash flow declined 48.76% from $3.3M to $1.69M.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D- from D on 3/25/2020 due to a significant decline in the valuation index, growth index and total return index. Earnings per share declined from $0.0513 to -$0.0771, and operating cash flow declined 48.76% from $3.3M to $1.69M.
D
Sell
9/26/2019Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D from D- on 9/26/2019 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 241.32% from $968 to $3.3M, EBIT increased 83.34% from $1.5M to $2.75M, and earnings per share increased from $0.03 to $0.0513.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D from D- on 9/26/2019 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 241.32% from $968 to $3.3M, EBIT increased 83.34% from $1.5M to $2.75M, and earnings per share increased from $0.03 to $0.0513.
D
Sell
6/20/2019Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D- from D on 6/20/2019 due to a decline in the volatility index and total return index.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D- from D on 6/20/2019 due to a decline in the volatility index and total return index.
D
Sell
5/15/2019Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D from D- on 5/15/2019 due to a significant increase in the valuation index and efficiency index. Net income increased 175.21% from -$1.09M to $816, and total capital increased 4.37% from $42.54M to $44.4M.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D from D- on 5/15/2019 due to a significant increase in the valuation index and efficiency index. Net income increased 175.21% from -$1.09M to $816, and total capital increased 4.37% from $42.54M to $44.4M.
D
Sell
5/7/2019Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D- from D on 5/7/2019 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 254.78% from $701 to -$1.09M, and total capital declined 5.64% from $45.08M to $42.54M.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D- from D on 5/7/2019 due to a significant decline in the valuation index, efficiency index and total return index. Net income declined 254.78% from $701 to -$1.09M, and total capital declined 5.64% from $45.08M to $42.54M.
D
Sell
11/14/2018Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D from D+ on 11/14/2018 due to a significant decline in the growth index, solvency index and valuation index. Operating cash flow declined 532.26% from $31 to -$134, EBIT declined 62.48% from $2.85M to $1.07M, and earnings per share declined from $0.0779 to $0.03.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D from D+ on 11/14/2018 due to a significant decline in the growth index, solvency index and valuation index. Operating cash flow declined 532.26% from $31 to -$134, EBIT declined 62.48% from $2.85M to $1.07M, and earnings per share declined from $0.0779 to $0.03.
D
Sell
8/16/2018Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D+ from D on 8/16/2018 due to a large increase in the growth index and valuation index. EBIT increased 356.57% from $624 to $2.85M, earnings per share increased from -$0.0492 to $0.0779, and total revenue increased 52.13% from $4.57M to $6.96M.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D+ from D on 8/16/2018 due to a large increase in the growth index and valuation index. EBIT increased 356.57% from $624 to $2.85M, earnings per share increased from -$0.0492 to $0.0779, and total revenue increased 52.13% from $4.57M to $6.96M.
D
Sell
6/5/2018Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D from D+ on 6/5/2018 due to a decline in the solvency index and volatility index.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D from D+ on 6/5/2018 due to a decline in the solvency index and volatility index.
D
Sell
5/21/2018Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D+ from D on 5/21/2018 due to a noticeable increase in the valuation index, efficiency index and solvency index. The quick ratio increased from 1.91 to 2.08, and debt to equity declined from 0.79 to 0.74.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D+ from D on 5/21/2018 due to a noticeable increase in the valuation index, efficiency index and solvency index. The quick ratio increased from 1.91 to 2.08, and debt to equity declined from 0.79 to 0.74.
D
Sell
5/10/2018Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D from D+ on 5/10/2018 due to a decline in the total return index, volatility index and solvency index.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D from D+ on 5/10/2018 due to a decline in the total return index, volatility index and solvency index.
D
Sell
3/1/2018Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D+ from D on 3/1/2018 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 39.43% from $2.74M to $3.82M, and total capital increased 5.91% from $38.77M to $41.06M.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D+ from D on 3/1/2018 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 39.43% from $2.74M to $3.82M, and total capital increased 5.91% from $38.77M to $41.06M.
D
Sell
11/3/2017Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D from D- on 11/3/2017 due to a noticeable increase in the solvency index, growth index and efficiency index. Operating cash flow increased 741.59% from $1.36M to $11.45M, net income increased 134.3% from $1.17M to $2.74M, and earnings per share increased from $0.0441 to $0.1.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D from D- on 11/3/2017 due to a noticeable increase in the solvency index, growth index and efficiency index. Operating cash flow increased 741.59% from $1.36M to $11.45M, net income increased 134.3% from $1.17M to $2.74M, and earnings per share increased from $0.0441 to $0.1.
D
Sell
8/11/2017Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D- from D on 8/11/2017 due to a decline in the growth index and efficiency index. Total capital declined 34.74% from $54.71M to $35.7M.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D- from D on 8/11/2017 due to a decline in the growth index and efficiency index. Total capital declined 34.74% from $54.71M to $35.7M.
D
Sell
6/22/2017Upgraded
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D from D- on 6/22/2017 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 952% from -$550 to $4.69M, and earnings per share increased from -$0.4294 to -$0.1257.
Cipher Pharmaceuticals Inc. (CPHRF) was upgraded to D from D- on 6/22/2017 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 952% from -$550 to $4.69M, and earnings per share increased from -$0.4294 to -$0.1257.
D
Sell
3/3/2017Downgrade
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D- from D on 3/3/2017 due to a significant decline in the efficiency index, solvency index and total return index. Debt to equity increased from 1.22 to 2.02, total capital declined 16.8% from $65.37M to $54.39M, and the quick ratio declined from 2.41 to 2.35.
Cipher Pharmaceuticals Inc. (CPHRF) was downgraded to D- from D on 3/3/2017 due to a significant decline in the efficiency index, solvency index and total return index. Debt to equity increased from 1.22 to 2.02, total capital declined 16.8% from $65.37M to $54.39M, and the quick ratio declined from 2.41 to 2.35.
D
Sell
8/23/2016Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to D from D+ on 8/23/2016 due to a large decline in the total return index, volatility index and efficiency index. Net income declined 25.13% from -$2.69M to -$3.37M, and total capital declined 2.49% from $87.44M to $85.26M.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to D from D+ on 8/23/2016 due to a large decline in the total return index, volatility index and efficiency index. Net income declined 25.13% from -$2.69M to -$3.37M, and total capital declined 2.49% from $87.44M to $85.26M.
D
Sell
5/6/2016Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to D+ from C- on 5/6/2016 due to a noticeable decline in the growth index, efficiency index and valuation index. Net income declined 232.06% from $2.04M to -$2.69M, earnings per share declined from $0.0783 to -$0.1, and total revenue declined 6.37% from $9.71M to $9.1M.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to D+ from C- on 5/6/2016 due to a noticeable decline in the growth index, efficiency index and valuation index. Net income declined 232.06% from $2.04M to -$2.69M, earnings per share declined from $0.0783 to -$0.1, and total revenue declined 6.37% from $9.71M to $9.1M.
C
Hold
3/11/2016Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to C- from C on 3/11/2016 due to a significant decline in the volatility index, solvency index and valuation index.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to C- from C on 3/11/2016 due to a significant decline in the volatility index, solvency index and valuation index.
C
Hold
2/25/2016Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to C from B- on 2/25/2016 due to a noticeable decline in the valuation index, growth index and efficiency index. Earnings per share declined from -$0.0853 to $0.0871, net income declined 192.06% from -$2.22M to $2.04M, and operating cash flow declined 16.72% from $1.56M to $1.3M.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to C from B- on 2/25/2016 due to a noticeable decline in the valuation index, growth index and efficiency index. Earnings per share declined from -$0.0853 to $0.0871, net income declined 192.06% from -$2.22M to $2.04M, and operating cash flow declined 16.72% from $1.56M to $1.3M.
B
Buy
2/18/2016Upgraded
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B- from C+ on 2/18/2016 due to an increase in the volatility index and valuation index.
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B- from C+ on 2/18/2016 due to an increase in the volatility index and valuation index.
C
Hold
2/2/2016Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to C+ from B- on 2/2/2016 due to a decline in the volatility index and total return index.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to C+ from B- on 2/2/2016 due to a decline in the volatility index and total return index.
B
Buy
1/13/2016Upgraded
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B- from C+ on 1/13/2016 due to an increase in the valuation index and volatility index.
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B- from C+ on 1/13/2016 due to an increase in the valuation index and volatility index.
C
Hold
12/29/2015Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to C+ from B- on 12/29/2015 due to a decline in the valuation index, total return index and volatility index.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to C+ from B- on 12/29/2015 due to a decline in the valuation index, total return index and volatility index.
B
Buy
11/25/2015Upgraded
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B- from C+ on 11/25/2015 due to an increase in the valuation index.
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B- from C+ on 11/25/2015 due to an increase in the valuation index.
C
Hold
11/10/2015Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to C+ from B- on 11/10/2015 due to a decline in the valuation index.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to C+ from B- on 11/10/2015 due to a decline in the valuation index.
B
Buy
11/5/2015Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B- from B+ on 11/5/2015 due to a significant decline in the valuation index, total return index and efficiency index. Total capital declined 0.92% from $86.78M to $85.98M.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B- from B+ on 11/5/2015 due to a significant decline in the valuation index, total return index and efficiency index. Total capital declined 0.92% from $86.78M to $85.98M.
B
Buy
8/31/2015Upgraded
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B+ from B on 8/31/2015 due to a noticeable increase in the valuation index, growth index and solvency index.
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B+ from B on 8/31/2015 due to a noticeable increase in the valuation index, growth index and solvency index.
B
Buy
8/14/2015Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B from B+ on 8/14/2015 due to a major decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.0967 to -$0.02, EBIT declined 91.86% from $3.44M to $280, and the quick ratio declined from 4.84 to 0.88.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B from B+ on 8/14/2015 due to a major decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.0967 to -$0.02, EBIT declined 91.86% from $3.44M to $280, and the quick ratio declined from 4.84 to 0.88.
B
Buy
6/16/2015Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B+ from A- on 6/16/2015 due to a major decline in the volatility index.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B+ from A- on 6/16/2015 due to a major decline in the volatility index.
A
Buy
6/1/2015Upgraded
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to A- from B on 6/1/2015 due to an increase in the valuation index.
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to A- from B on 6/1/2015 due to an increase in the valuation index.
B
Buy
5/19/2015Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B from B+ on 5/19/2015 due to a decline in the valuation index, solvency index and volatility index. The quick ratio declined from 5.24 to 4.84.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B from B+ on 5/19/2015 due to a decline in the valuation index, solvency index and volatility index. The quick ratio declined from 5.24 to 4.84.
B
Buy
5/12/2015Upgraded
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B+ from B on 5/12/2015 due to an increase in the valuation index.
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B+ from B on 5/12/2015 due to an increase in the valuation index.
B
Buy
4/20/2015Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B from B+ on 4/20/2015 due to a decline in the volatility index and valuation index.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B from B+ on 4/20/2015 due to a decline in the volatility index and valuation index.
B
Buy
3/26/2015Upgraded
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B+ from B on 3/26/2015 due to an increase in the valuation index and volatility index.
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B+ from B on 3/26/2015 due to an increase in the valuation index and volatility index.
B
Buy
3/6/2015Downgrade
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B from B+ on 3/6/2015 due to a substantial decline in the valuation index and growth index. Earnings per share declined from $0.3031 to $0.1242, and operating cash flow declined 22.74% from $6.55M to $5.06M.
Cipher Pharmaceuticals Inc. (CPHR) was downgraded to B from B+ on 3/6/2015 due to a substantial decline in the valuation index and growth index. Earnings per share declined from $0.3031 to $0.1242, and operating cash flow declined 22.74% from $6.55M to $5.06M.
B
Buy
3/2/2015Upgraded
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B+ from B on 3/2/2015 due to a noticeable increase in the volatility index and valuation index.
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B+ from B on 3/2/2015 due to a noticeable increase in the volatility index and valuation index.
B
Buy
12/1/2014Upgraded
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B from C on 12/1/2014 due to a significant increase in the growth index, total return index and efficiency index. Earnings per share increased from $0.1559 to $0.3031, net income increased 92.44% from $4.13M to $7.95M, and operating cash flow increased 60.67% from $4.08M to $6.55M.
Cipher Pharmaceuticals Inc. (CPHR) was upgraded to B from C on 12/1/2014 due to a significant increase in the growth index, total return index and efficiency index. Earnings per share increased from $0.1559 to $0.3031, net income increased 92.44% from $4.13M to $7.95M, and operating cash flow increased 60.67% from $4.08M to $6.55M.
C
Hold
6/2/2014Upgraded
Cipher Pharmaceuticals Inc. (CPHMF) was upgraded to C from C- on 6/2/2014 due to a substantial increase in the valuation index, efficiency index and solvency index. The quick ratio increased from 3.18 to 4.24, and total capital increased 7.18% from $36.48M to $39.1M.
Cipher Pharmaceuticals Inc. (CPHMF) was upgraded to C from C- on 6/2/2014 due to a substantial increase in the valuation index, efficiency index and solvency index. The quick ratio increased from 3.18 to 4.24, and total capital increased 7.18% from $36.48M to $39.1M.
C
Hold
3/3/2014Upgraded
Cipher Pharmaceuticals Inc. (CPHMF) was upgraded to C- from D+ on 3/3/2014 due to a noticeable increase in stability, valuation and growth.
Cipher Pharmaceuticals Inc. (CPHMF) was upgraded to C- from D+ on 3/3/2014 due to a noticeable increase in stability, valuation and growth.
OTC PK
03/07/2025 3:54PM Eastern
Quotes delayed
